Fetal loss can be spontaneous or induced following findings on the anomaly scan. This study aims to (1) ascertain referral rates and patterns of referral to clinical genetics (CG) triggered by postmortem (PM) findings and (2) improve the quality of care offered to those families at risk of recurrence. A review of all PM reports during 2007 and 2008 was undertaken. We collected clinical and demographic information on all those cases in which a recommendation for referral had been or should have been made. During the study period, 549 PMs were conducted, of which 72 (13%) had a recommendation for referral to CG. A further 30 (5%) cases were identified in which a recommendation for referral to CG should have been made. Of the 72 cases with a recommendation for referral to CG, 54 cases were identified within the catchment area. Of these, 29 (54%) resulted in a referral to Sheffield CG, with an average of 17 weeks' waiting time for referral. In >90% of cases it was possible to clarify diagnosis and offer additional information. A small proportion of families declined referral to CG. By mapping the process from PM report to potential referral to CG, we have been able to highlight areas of clinical concern and improve clinical practice. This study has also enabled us to gain a better understanding of the patient referral and clinical care pathways involved. This, in turn, has provided a clinical focus within the joint histopathology-genetics multidisciplinary meetings to enable discussion of potential referrals.

Aim To investigate European Society of Cardiology (ESC) Guidelines' 'typical' and 'less typical', and 'non-ESC' symptoms associated with heart failure, and ESC typical and less typical symptoms regarding setting, age, and sex. Methods A mixed-method systematic review and narrative synthesis. Systematic search was carried out in six electronic databases. Quality was assessed using Joanna Briggs Institute (JBI) critical appraisal checklists. Symptoms were grouped into typical and less typical, and non-guidelines symptoms. Differences in typical and less typical symptoms were investigated in hospital versus community settings, <65 versus 65 years old age, and men versus women. Results 37 papers (26 quantitative, 8 qualitative and 3 mixedmethod research) were included. 62% of participants were male. Mean age was 66 (48-82). Participants in 36 studies reported at least one of 6 typical, whereas less typical (n=10) and non-Guidelines n=37) symptoms were observed in 35 and 37 studies, respectively. Most observed symptoms of each group were: Breathlessness (typical-78%, n=3659); cough (less typical-48%, n=3450); and lack of energy (non-ESC-69%, n=1758). Less typical symptoms (cough, wheezing, palpitation, and dizziness) were different between hospital and communitydwelling cohorts. Typical symptoms (orthopnoea, paroxysmal nocturnal dyspnoea, and swelling) were higher in cohorts 65 years old age. Due to the paucity of women's perspectives in studies, there was little information available to compare the symptom experiences of men and women. Conclusion A comprehensive individual symptom assessment will be required to provide more focused and person-centred care. Thus, clinical management guidelines should include the full spectrum of symptoms in different phases of heart failure (especially, palliative and end of life care).

Background. Commercial weight loss programs provide valuable consumer options for those desiring support. Several commercial programs are reported to produce ≥3-fold greater weight loss than self-directed dieting. The effectiveness of JumpstartMD, a commercial pay-as-you-go program that emphasizes a low-to-very-low-carbohydrate real-food diet and optional pharmacologic treatment without prepackaged meals or meal replacement, has not previously been described. Methods. Completer and last observation carried forward (LOCF) of clinic-measured weight loss (kg) in 18,769 female and 3638 male JumpstartMD participants. Results. Completers lost (mean ± SE) 8.7 ± 0.04 kg, 9.5 ± 0.04% with 44.5 ± 0.5% achieving ≥10% weight loss at 3 months (mo, N = 14,999 completers); 11.8 ± 0.1 kg, 12.6 ± 0.1% with 66.4 ± 0.6% achieving ≥10% weight loss at 6 mo (N = 11,805); and 11.5 ± 0.2 kg, 12.0 ± 0.2% with 57.6 ± 0.9% achieving ≥10% weight loss at 12 mo (N = 8514). LOCF estimates were −6.5 ± 0.03 kg, −7.2 ± 0.03% with 27.1 ± 0.3% achieving ≥10% weight loss at 3 mo; −7.7 ± 0.04 kg, −8.5 ± 0.04% with 36.3 ± 0.3% achieving ≥10% weight loss at 6 mo; and −7.7 ± 0.1 kg, −8.4 ± 0.1% with 34.6 ± 0.3% achieving ≥10% weight loss after 12 mo. Frequent health coach meetings was a major determinant of weight loss, with women and men attending ≥75% of their weekly appointments losing 8.8 ± 0.04 and 11.9 ± 0.1 kg, respectively, after 3 mo, 13.1 ± 0.1 and 16.5 ± 0.3 kg after 6 mo, and 16.5 ± 0.3 and 19.4 ± 0.8 kg after 12 mo. Phentermine and phendimetrazine had a minor effect in women only at 1 (6.1% greater weight loss than untreated), 2 (4.1%), and 3 mo (1.2%), but treated patients showed longer enrollment than nontreated during the first 3 (females: +0.4 ± 0.01; males: +0.3 ± 0.04 mo), 6 (females: +1.1 ± 0.04; males: +1.0 ± 0.1 mo), and 12 mo (females: +2.7 ± 0.1; males: +2.4 ± 0.2 mo). JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets. Conclusion. A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.

No abstract